缺血性脑卒中伴高血压病患者个体化精准治疗的研究  

Individualized precision therapy for patients with ischemic stroke and hypertension

作　　者：付虹[1] 田磊[1] FU Hong;TIAN Lei(Affiliated Hospital of Nanjing University of Traditional Chinese Medicine,Nanjing 210029,Jiangsu,China)

机构地区：[1]南京中医药大学附属医院,江苏南京210029

出　　处：《中国临床药理学与治疗学》2022年第8期870-876,共7页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：江苏省药学会-奥赛康临床药学基金科研项目(A201902);江苏省中医院院级科研项目(Y200220)。

摘　　要：目的:通过对缺血性脑卒中伴高血压病的患者进行CYP3A5基因检测,探讨基因多态性对钙通道阻滞剂降压疗效的影响。方法:纳入108例缺血性脑卒中伴高血压病的患者,分为试验组和对照组,各54例,试验组根据基因检测结果分别选择苯磺酸氨氯地平片和苯磺酸左旋氨氯地平片,对照组全部选择苯磺酸氨氯地平片,考察两组患者降压疗效。结果:两组患者从一般资料和实验室检查指标来看,具有可比性。两组的有效率比较显示,试验组有效率77.78%,对照组有效率57.41%(P<0.05)。试验组基因型为GG型和AG型的患者在服用苯磺酸氨氯地平片后降压疗效明显高于AA型患者,且GG型的患者较AG型患者在服用苯磺酸氨氯地平片后降压效果更强。结论:检测CYP3A5的基因多态性,对缺血性脑卒中伴高血压病的患者个体化服用钙通道阻滞剂控制血压具有指导意义。AIM:To investigate the influence of CYP3A5 gene polymorphism on the anti-hypertensive efficacy of calcium channel blocker in patients with ischemic stroke and hypertension.METHODS:A total of 108 cases of ischemic stroke patients with hypertension were included and divided into experimental group and control group,and 54 cases in each group,the experimental group selected amlodipine tablets and levamlodipine tablets respectively according to the results of genetic testing,while the control group selected amlodipine tablets,which in order to investigate the antihypertensive efficacy of the two groups.RESULTS:The effective rate of experimental group and control group was 77.78%and 57.41%(P<0.05).In the experimental group,the antihypertensive effect of GG and AG genotype patients after taking amlodipine tablets was significantly higher than that of AA type patients,and GG type patients had a stronger antihypertensive effect than AG type patients after taking amlodipine tablets.CONCLUSION:CYP3A5 gene polymorphism is very important for blood pressure control by calcium channel blockers in patients with ischemic stroke and hypertension.

关 键 词：缺血性脑卒中 高血压病 CYP3A5 基因多态性 钙通道阻滞剂 

分 类 号：R743.3[医药卫生—神经病学与精神病学]